Anti-CD11a monoclonal antibody KBA
Latest Information Update: 01 Sep 1998
At a glance
- Originator Nonindustrial source
- Class Monoclonal antibodies
- Mechanism of Action CD11a antigen antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Transplant rejection